Le microbiote inspire la Bourse : la biotech lyonnaise MaaT Pharma lève 31,5 millions d’euros - MaaT Pharma

To read the article, click here!

Previous PostMaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
Next PostRecherche contre les cancers : la biotech lyonnaise MaaT Pharma ouvre son capital pour accélérer son développement

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club